Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807967 | 1.00 | POLB (0.43) | POLBKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL18498477 | 0.88 | POLB (0.40) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL21807985 | 0.88 | POLB (0.40) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL18498471 | 0.85 | SMN1; SMN2 (0.49) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL18498468 | 0.85 | SMN1; SMN2 (0.49) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL18498475 | 0.84 | POLB (0.47) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL18498466 | 0.84 | POLB (0.47) | POLBSMN1; SMN2NPC1RAB9APTPN1 | |
| SCHEMBL21807961 | 0.83 | PTPN1 (0.54) | POLBKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL26071423 | 0.83 | PTPN1 (0.54) | POLBKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL21808068 | 0.80 | POLB (0.48) | POLBSMN1; SMN2NPC1RAB9APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | POLB 956/4885KDM4E 4064/4885SMN1; SMN2 9/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | POLB 956/4885KDM4E 4064/4885SMN1; SMN2 9/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | POLB 956/4885KDM4E 4064/4885SMN1; SMN2 9/4885 |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | POLB 956/4885KDM4E 4064/4885SMN1; SMN2 9/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | POLB 956/4885KDM4E 4064/4885SMN1; SMN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.